Journal ID (nlm-ta): Clin Infect Dis
Journal ID (iso-abbrev): Clin Infect Dis
Journal ID (publisher-id): cid
Title:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society
of America
Publisher:
Oxford University Press
(US
)
ISSN
(Print):
1058-4838
ISSN
(Electronic):
1537-6591
Publication date Collection: 01
December
2021
Publication date
(Electronic):
16
June
2021
Publication date PMC-release: 16
June
2021
Volume: 73
Issue: 11
Pages: 2009-2022
Affiliations
[1
]
Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina, USA
[2
]
Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health , Boston, Massachusetts, USA
[3
]
University of Cincinnati , Cincinnati, Ohio, USA
[4
]
Massachusetts General Hospital , Boston, Massachusetts, USA
[5
]
University of Alabama at Birmingham , Birmingham, Alabama, USA
[6
]
Icahn School of Medicine at Mount Sinai , New York, New York, USA
[7
]
University of California at Los Angeles , Los Angeles, California, USA
[8
]
Kowa Pharmaceuticals America, Inc. , Montgomery, Alabama, USA
[9
]
Gilead Sciences, Inc. , Foster City, California, USA
[10
]
HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research
Centre, and Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University , Thailand
[11
]
Hospital Geral de Nova Iguacu , Rio de Janeiro,Brazil
[12
]
Hospital San Carlos , Madrid, Spain
[13
]
Hospital de Bellvitge, l’Hospitalet de Llobregat , Spain
[14
]
University of Texas Southwestern Medical Center , Dallas, Texas, USA
Author notes
Correspondence: P. S. Douglas, Duke University School of Medicine, Duke Clinical Research
Institute, PO Box 17969, 200 Morris St, Rm 7710, Durham, NC 27715 (
pamela.douglas@
123456duke.edu
).
Author information
Article
Publisher ID:
ciab552
DOI: 10.1093/cid/ciab552
PMC ID: 8664454
PubMed ID: 34134131
SO-VID: 80cbc497-dfc2-4b76-812c-7891031e7696
Copyright © © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases
Society of America.
License:
This is an Open Access article distributed under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs licence (
https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any
medium, provided the original work is not altered or transformed in any way, and that
the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Funded by:
National Heart, Lung, and Blood Institute, DOI 10.13039/100000050;
Award ID: 5K24HL113128
Award ID: 5T32HL076136
Award ID: HL137562
Award ID: HL146199
Funded by:
National Institute of Allergy and Infectious Diseases, DOI 10.13039/100000060;
Award ID: UM1 AI068636
Award ID: UM1 AI106701
Award ID: P30 DK 040561
Award ID: R01 MD013493
Funded by:
Oregon Health and Science University, DOI 10.13039/100006668;
Award ID: 13FTF16450001
Funded by:
Columbia University, DOI 10.13039/100006474;
Funded by:
National Institutes of Health, DOI 10.13039/100000002;
Award ID: 5R01-HL109711
Award ID: R01 MD013493
Award ID: R01AI123001
Award ID: R01HL137562
Award ID: R01HL146267
Award ID: U01HL123336
Award ID: U01HL123336
Award ID: R01HL151283
Funded by:
Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare;
Funded by:
NIA, DOI 10.13039/100000049;
Award ID: R01 AG054366
Funded by:
NIAID, DOI 10.13039/100000060;
Award ID: UM1 AI068634
Award ID: AI068634
Award ID: AI123001
Funded by:
Statistical and Data Management Center;
Funded by:
AIDS Clinical Trials Group, DOI 10.13039/100006392;
Award ID: U01 HL123339
Funded by:
REPRIEVE DCC;
Funded by:
REPRIEVE-EU;
Funded by:
Amgen, Cytodyn, ViiV Healthcare, Merck, Janssen, and Pfizer;
Funded by:
KOWA;
Funded by:
Gilead, ViiV Healthcare, and GSK;
Funded by:
Merck, ViiV Healthcare, and Theratechnologies;
Funded by:
Infectious Disease Society of America;
Funded by:
American College of Cardiology, DOI 10.13039/100005485;
Funded by:
Gilead, Merck, Emergent Biosolutions, Glaxo-Smith-Kline, Janssen, Atea, Frontier Technology,
Pfizer, Viiv Healthcare, and Regeneron;
Funded by:
Kowa Pharmaceuticals;
Funded by:
Gilead and ViiV Healthcare;
Funded by:
Gilead, Janssen, Merck Sharp and Dohme;
Funded by:
Amarin, BMS, Esperion, Amgen, Sanofi, Regeneron, and Janssen;
Funded by:
Amarin, Amgen, Astra Zeneca, BI, CSL, Esperion, Janssen, Lilly, Sanofi, Regeneron,
NovoNordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89Bio, and Pfizer;
Funded by:
KOWA;
Funded by:
KOWA;
Funded by:
ViiV Healthcare and Theratechnologies;
Funded by:
KOWA;
Funded by:
Gilead, and ViiV;